Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Lineage Cell Therapeutics, Inc. LCTX

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, a oligodendrocyte progenitor cell therapy for...

Recent & Breaking News (NYSEAM:LCTX)

BioTime Management to Present at Rodman & Renshaw 17th Annual Global Investment Conference

Business Wire August 28, 2015

The Wistar Institute and BioTime Subsidiary OncoCyte Corporation Expand Agreement to Develop Molecular Diagnostic Test for the Detection of Lung Cancer

Business Wire August 18, 2015

BioTime, Inc. Reports Second Quarter 2015 Results and Recent Developments

Business Wire August 10, 2015

BioTime Announces the Issuance of 27 New Patents Protecting Stem Cell-Based Product Development

Business Wire August 10, 2015

OncoCyte Announces Appointment of Andy Arno to Board of Directors

Business Wire July 15, 2015

William Annett Named Chief Executive Officer of OncoCyte Corporation

Business Wire June 16, 2015

BioTime to Present at the Jefferies 2015 Global Healthcare Conference

Business Wire May 20, 2015

OncoCyte's Collaborators at The Wistar Institute Present Positive Clinical Interim Results of Blood-Based Diagnostic Test for Non-Invasive Detection of Lung Cancer

Business Wire May 19, 2015

OncoCyte Corporation Completes Equity Financing Round

Business Wire May 14, 2015

BioTime's Subsidiary Cell Cure Neurosciences Ltd. Awarded $1.6 Million Grant From Israel's Office of the Chief Scientist

Business Wire May 13, 2015

BioTime, Inc. Reports First Quarter 2015 Results and Recent Corporate Accomplishments

Business Wire May 11, 2015

Cell Cure Neurosciences Announces Preclinical Efficacy Data Demonstrating OpRegen® Preserves Vision

Business Wire May 4, 2015

BioTime's Clinical Grade Stem Cells From Subsidiary ES Cell International to Be Used in Planned CIRM-Funded Preclinical Studies of Huntington's Disease

Business Wire April 27, 2015

BioTime Licenses Beckman Research Institute of City of Hope to Manufacture Clinical Grade Stem Cells

Business Wire April 22, 2015

OncoCyte Announces Initial Data From Ongoing Clinical Study of Collagen Type X as a Marker and Potential Diagnostic for Breast Cancer and Other Types of Human Cancers

Business Wire April 20, 2015

OncoCyte Announces Availability of Abstracts With New Clinical Data From Studies of PanC-Dx(TM) Cancer Diagnostic in Bladder and Breast Cancer

Business Wire March 20, 2015

BioTime, Inc. Reports Fourth Quarter and Fiscal Year End 2014 Financial Results and Recent Corporate Accomplishments

Business Wire March 11, 2015

Icahn School of Medicine at Mount Sinai and LifeMap Solutions Launch Asthma Study for iPhone

Business Wire March 9, 2015

BioTime Announces First Patient Treated in Pivotal Clinical Trial of Renevia(TM) for HIV-Associated Lipoatrophy

Business Wire February 24, 2015

Cell Cure Neurosciences Ltd. Provides Update on its Product Development and Partnering Activities

Business Wire February 17, 2015